Thomas Stankovich - Jun 15, 2021 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Stock symbol
RSLS
Transactions as of
Jun 15, 2021
Transactions value $
-$14,137
Form type
4
Date filed
6/17/2021, 04:06 PM
Next filing
Sep 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Disposed to Issuer -$14.1K -4.64K -100% $3.05* 0 Jun 15, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, Obalon Therapeutics, Inc. ("Obalon"), and Optimus Merger Sub, Inc., which became effective on June 15, 2021, in exchange for 2,613 shares of common stock of Obalon having a market value of $3.05 per share at the effective time of the merger.